GlaxoSmithKline announced today that its long-acting drug Apret (cabotegravir injection) is officially launched for HIV-1 pre-exposure prophylaxis (PrEP) in adults and adolescents (weighing ≥35kg) at risk of infection, to reduce the risk of sexually transmitted HIV-1 infection, in combination with safe sexual behavior measures for better HIV-1 PrEP outcomes. As of January 2025, the cabotegravir long-acting regimen is the first and only long-acting injection approved for HIV pre-exposure prophylaxis by the National Medical Products Administration of China.
- Latest
- Detail
葛兰素史克HIV暴露前预防长效药物艾普特在中国上市
GlaxoSmithKline's long-acting drug Apret for HIV pre-exposure prophylaxis has been launched in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Unlock the Full List
Latest
18:45
Shanghai Stock Exchange: This week, regulatory measures such as written warnings were taken against 58 cases of abnormal securities trading behaviors including market manipulation and false declarations, and special investigations were conducted on 15 significant matters of listed companies. One suspected illegal case was reported to the Securities Regulatory Commission.
18:44
According to documents from the Hong Kong Stock Exchange, Xiaomi Group repurchased 279,800 Class B shares on January 10, costing 9.4 million HKD.
HKEX-0.85%
18:40
The newly elected President of Lebanon meets with the caretaker Prime Minister to discuss regional issues and other topics.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.